Testing and Diagnostics Library
Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 145–168 of 314
Personalized Skin Simulation Predicts Individual Product Response
Haut.AI's integration with Olay uses AI-driven image analysis and skin simulation to generate personalized product recommendations based on individual skin features and clinical data. This technology bridges the gap between generic skincare advice and individualized prediction of product efficacy, enabling consumers to visualize expected outcomes before committing to regimens.
[Personal View] Responsible use of artificial intelligence in the provision of long-term care for older people: a care-centric approach
AI implementation in long-term care for older people risks compromising care quality when framed narrowly around workforce efficiency rather than centered on care outcomes and ethical implications. A care-centric approach requires understanding how automation affects the complex relational and systemic structures that support health across the lifespan.
Spontaneous speech enables scalable digital phenotyping of physical functional deficits in aging
Analysis of spontaneous speech patterns—including acoustic features, linguistic markers, and speech rate—can identify physical functional decline in aging populations with accuracy comparable to formal physical assessments. This approach enables remote, scalable detection of mobility and strength deficits without requiring in-person testing.
AI Drug Discovery Cuts Development Timelines for Aging-Related Therapeutics
Insilico Medicine and Takeda established a strategic collaboration using generative AI models to accelerate drug discovery across multiple therapeutic areas, with potential deal value reaching $600 million. This partnership demonstrates how computational approaches can compress early-stage drug development timelines by optimizing molecular properties before clinical validation begins.
Blood proteins predict liver disease 16 years early
A five-protein panel in blood plasma can identify individuals at high risk for metabolic dysfunction-associated steatotic liver disease up to 16 years before clinical diagnosis. This extends the window for intervention substantially earlier than current clinical detection methods allow.
AliveCor shrinks the ECG and speeds up diagnosis
AliveCor's Kardia 12L is a handheld, AI-assisted device that captures 12-lead ECG-quality cardiac data with simplified hardware and reduced setup time. The CE-marked system detects 35 cardiac conditions and reduces testing time by approximately one-third, extending hospital-grade diagnostic capacity into primary care, rural, and home settings.
New AI research reshapes neuroprotective drug discovery funding
Artificial intelligence is accelerating neuroprotective drug discovery across target identification, molecular design, and clinical optimization, with hundreds of millions in venture funding flowing into AI-driven neuroscience companies and major pharma investing in AI-enabled development platforms. This shift compresses timelines for bringing neuroprotective agents to market and expands the addressable therapeutic space for neurodegeneration.
AI meets ALS in £7.5 million Longitude Prize
A £7.5 million global challenge prize has awarded £2 million in discovery funding to 20 international teams tasked with identifying new drug targets for amyotrophic lateral sclerosis using artificial intelligence and integrated multi-omics data. The initiative targets the upstream bottleneck in ALS research—mechanistic target identification—rather than late-stage drug development, reflecting a strategic shift toward data-centric, predictive approaches to neurodegenerative disease.
Partnership brings new AI model promising faster drug discovery
Insilico Medicine and Liquid AI have developed LFM2-2.6B-MMAI, a compact AI model that performs drug discovery tasks with efficiency matching much larger systems while maintaining data privacy through on-premise deployment. This acceleration of early-stage compound identification and optimization directly shortens timelines for therapies targeting age-related diseases.
Antioxidant vitamin index and risk of age-related macular degeneration: multicenter validation and clinical translation
A multicenter validation study establishes a quantifiable antioxidant vitamin index that predicts age-related macular degeneration risk, enabling clinicians to stratify patients and intervene with targeted nutritional strategies before vision loss occurs.
Trajectories of physical function and biological aging in generally healthy older adults with and without incident invasive cancer over a three-year follow-up: findings from the DO-HEALTH study
Older adults who developed cancer over three years showed accelerated decline in physical function and biological aging markers compared to cancer-free peers, even when starting from similar baseline health. Physical deterioration preceded or accompanied cancer diagnosis, suggesting measurable functional decline tracks with malignant disease progression.
Blood-brain barrier testing accelerated through AI-powered cell models
Frontier Bio's NeuroTraX-AI platform combines human cell-based tissue models with machine learning to measure blood-brain barrier integrity from unlabeled microscope images, enabling faster and lower-cost screening of potential neurotherapeutics. This represents a shift from animal testing toward human-relevant tissue systems that better predict how candidate treatments interact with the central nervous system.
Causal AI in Drug Discovery Moves Beyond Correlation
Relation Therapeutics developed MORGAN, a foundation model trained on perturbation datasets to identify causal mechanisms rather than statistical associations in drug discovery. This shift from correlational to mechanistic understanding addresses a critical gap in how biomarkers are interpreted, with implications for targeting interventions across age-related diseases including immunology, metabolic dysfunction, and bone disorders.
BioAge Labs Provides Business Updates
BioAge Labs reported positive interim Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory cardiovascular biomarkers (hsCRP 86%, IL-6 58%, fibrinogen 30%) and brain penetration. The company is advancing toward Phase 2a trials in cardiovascular disease and expanding into ophthalmology for diabetic macular edema, positioning the compound as a multi-indication anti-inflammatory therapy.
This MRI doesn’t wait until brain surgery is over
Intraoperative MRI technology enables surgeons to image the brain during active neurosurgery, reducing procedure time by one to two hours and allowing real-time adjustments based on functional data rather than preoperative imaging. This capability addresses a fundamental constraint in neurosurgical care: the gap between what the surgeon sees at the start of an operation and the patient's actual physiological state during intervention.
Early protein detection redirects neurodegenerative disease treatment
Amprion's funding expansion addresses a critical bottleneck in neurodegenerative disease treatment: accurate early diagnosis. The company's Seed Amplification Assay detects pathological protein signatures that distinguish between diseases with overlapping symptoms, potentially accelerating therapeutic development by ensuring the right patients enter clinical trials.
Ribo, Insilico partner to accelerate siRNA drug development using AI
Ribo and Insilico Medicine are collaborating to accelerate siRNA drug development by combining siRNA capabilities with AI-powered target discovery and molecule design. siRNA therapeutics can selectively silence disease-causing genes with rapid development timelines and extended therapeutic duration.
Cortechs.ai partners with Siemens Healthineers to expand NeuroQuant access
Cortechs.ai and Siemens Healthineers have partnered to integrate NeuroQuant, an FDA-cleared AI neuroimaging tool, into clinical workflows for automated brain lesion tracking and volumetric quantification. This expands clinician access to objective, longitudinal brain imaging data for monitoring neurological disease progression and treatment response, including anti-amyloid therapies for Alzheimer's disease.
Human Cell Models Replace Animal Testing in Drug Discovery
Greenstone and Intel are integrating human induced pluripotent stem cell biobanks with edge AI computing to accelerate drug discovery and safety assessment. This partnership addresses a fundamental gap in translational medicine: the poor predictive validity of animal models for human drug response and toxicity.
Sequential banks $3.5m for smarter skin health
Sequential, a Cambridge-based skin health testing company, raised $3.5 million to build an AI discovery engine powered by over 50,000 clinical samples and 4,000+ ingredients. The platform measures microbial and host biomarkers to identify which ingredients actually affect skin function—moving personal care from marketing claims to measurable biological outcomes.
Blood-based AT(N) biomarkers for Alzheimer’s disease and frontotemporal lobar degeneration in Latin America
Plasma biomarkers (phosphorylated tau, amyloid-beta, and neurofilament light) accurately distinguish Alzheimer's disease from frontotemporal lobar degeneration across Latin American populations when integrated with neuroimaging and machine learning algorithms. This addresses a critical gap in early detection capability for underrepresented populations.
[Articles] Incidental findings and duty-of-care protocols in cardiovascular magnetic resonance among older adults: a prospective population-based study from MyoFit46
Cardiovascular magnetic resonance imaging in adults over 75 reveals frequent incidental findings, demonstrating that large-scale aging cohorts require structured protocols for identifying, communicating, and managing unexpected discoveries. This work establishes a baseline for governance frameworks in gerontological research.
AI-Designed Compound Targets Dry Eye and Macular Degeneration
Insilico Medicine has nominated ISM9077, an AI-designed compound targeting a previously undrugged protein, as a preclinical candidate for dry age-related macular degeneration, uveitis, and dry eye disease. Preclinical data show the molecule outperforms current therapies across these indications while maintaining favorable pharmacokinetic properties for both oral and topical administration.
Tau tangles now detectable in blood with attomolar precision
Alamar Biosciences has developed a blood-based assay capable of measuring eMTBR-Tau, a tau-specific biomarker associated with brain cell damage and cognitive decline in Alzheimer's disease. This addresses a critical gap in current diagnostics: while existing blood tests detect amyloid accumulation, they cannot distinguish between people who will develop dementia and those who will not—a distinction tau pathology helps clarify.